| ulixertinib (BVD-523) / BioMed Valley Discoveries |
NCT03417739: A Phase II Study of BVD-523 in Metastatic Uveal Melanoma |
|
|
| Active, not recruiting | 2 | 13 | US | BVD-523, Ulixertinib | Dana-Farber Cancer Institute, BioMed Valley Discoveries, Inc | Uveal Melanoma | 05/20 | 08/25 | | |
BVD-523-ABC, NCT04488003: Study of Ulixertinib for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations |
|
|
| Terminated | 2 | 104 | US | Ulixertinib, BVD-523, BVD523, Physician's Choice | BioMed Valley Discoveries, Inc | Advanced Solid Tumor, BRAF Gene Mutation, BRAF Gene Alteration, MEK Mutation, MEK Alteration, MAP2K1 Gene Mutation, MAP2K1 Gene Alteration, MAP2K2 Gene Mutation, MAP2K2 Gene Alteration | 02/23 | 05/23 | | |
NCT05221320: Trial of Ulixertinib in Combination With Hydroxychloroquine in Patients With Advanced Gastrointestinal (GI) Malignancies |
|
|
| Recruiting | 2 | 215 | US | Ulixertinib, BVD-523, BVD523, Hydroxychloroquine | BioMed Valley Discoveries, Inc | Tumor, Solid, Gastrointestinal Cancer | 12/24 | 03/25 | | |
NCT06411821: Ulixertinib in People With Histiocytic Neoplasms |
|
|
| Recruiting | 2 | 38 | US | Ulixertinib, BVD-523 | Memorial Sloan Kettering Cancer Center, BioMed Valley Discoveries, Inc | Histiocytic Neoplasms | 05/27 | 05/27 | | |
NCT02296242: Phase 1/2 Study of the ERK1/2 Inhibitor BVD-523 in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndromes |
|
|
| Completed | 1/2 | 53 | US | BVD-523 | BioMed Valley Discoveries, Inc | Acute Myelogenous Leukemia, Myelodysplastic Syndrome | 06/17 | 06/17 | | |
NCT01781429: Phase I Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of BVD-523 in Patients With Advanced Malignancies |
|
|
| Completed | 1/2 | 136 | US | BVD-523 | BioMed Valley Discoveries, Inc | Advanced Solid Tumors | 02/18 | 09/18 | | |
